UK markets open in 5 hours 25 minutes

NeuroMetrix, Inc. (NURO)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
4.4000+0.0500 (+1.15%)
At close: 04:00PM EDT
4.5300 +0.13 (+2.95%)
After hours: 04:12PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close4.3500
Open4.4700
Bid4.2000 x 100
Ask0.0000 x 0
Day's range4.2500 - 4.6632
52-week range2.7000 - 9.8400
Volume30,322
Avg. volume47,226
Market cap8.741M
Beta (5Y monthly)2.32
PE ratio (TTM)N/A
EPS (TTM)-6.4200
Earnings date07 May 2024 - 12 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend date28 Mar 2007
1y target estN/A
  • Simply Wall St.

    NeuroMetrix, Inc.'s (NASDAQ:NURO) CEO Might Not Expect Shareholders To Be So Generous This Year

    Key Insights NeuroMetrix to hold its Annual General Meeting on 30th of April CEO Shai Gozani's total compensation...

  • GlobeNewswire

    NeuroMetrix Announces Steps Taken to Enhance Shareholder Value

    Joshua S. Horowitz joins Board of DirectorsAt-the-market equity facility terminated WOBURN, Mass., April 19, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ: NURO) today announced two steps to enhance shareholder value following feedback and recommendations from one of its largest shareholders, Ephraim Fields of Echo Lake Capital. The Board has approved the appointment of Joshua S. Horowitz as a new independent director with a 1-year term. Mr. Horowitz is a professional investor with over 22

  • GlobeNewswire

    NeuroMetrix Announces Publication of Study Demonstrating that DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy

    WOBURN, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) noted the recent publication of a large study demonstrating that DPNCheck® combined with standard EKG or DPNCheck alone accurately detects diabetic peripheral neuropathy (DPN). Hayashi and colleagues evaluated 167 patients with Type 1 or Type 2 diabetes. The reference standard for DPN was a gold standard nerve conduction study. The authors developed a predictive formula based on DPNCheck measurements, patient age